<DOC>
	<DOCNO>NCT00508209</DOCNO>
	<brief_summary>The prognosis retreat high-dose melphalan stem cell support first relapse high-dose treatment dependent time first relapse . Bortezomib increase chemosensitivity e.g . melphalan . The trial aim determine toxicity add bortezomib high-dose melphalan stem cell support evaluate whether time second relapse prolong .</brief_summary>
	<brief_title>Bortezomib High-dose Melphalan Myeloma Relapse</brief_title>
	<detailed_description>Patients multiple myeloma first treatment demand relapse initial treatment high-dose melphalan autologous stem cell support 2.0 x 10^6 CD34+ stem cell pr kg bodyweight freezer include trial . After disease status basic clinical biochemistry , M-protein blood urine , bone marrow investigation include immunophenotyping total skeletal x-ray patient treat three course standard bortezomib ( 1.3 mg/sqm Days 1,4,8,11 ) dexamethasone 20 mg day 1,2,4,5,8,9,11,12 . Within 4 week patient receive bortezomib day -5 -2 , high-dose melphalan ( 200 mg/sqm ) day -2 , subsequent least 2.0 x 10^6 CD34+ stem cell pr kg body weight . The first month high-dose therapy patient follow closely toxicity accord National Cancer Institute Common Toxicity Criteria Adverse Events ( NCI CTCAE ) , Version 3.0 . The patient evaluate response accord EBMT criterion event ( death progressive disease ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>First relapse ASCT Symptomatic myeloma More 2,0 x 10^6 CD34+ stem cell / kg bodyweight freezer stem cell support Signed informed consent give prior study related activity perform Age &gt; 18 year Allogeneic transplantation schedule part treatment Expected survival le one month . Performance status ( WHO ) &gt; 3 Neuropathy &gt; Grade 3 ( neurological symptom interfere ADL ) Nonsecreting myeloma Other concurrent disease make bortezomib treatment unsuitable Positive pregnancy test ( applicable woman childbearing potential ) Has know suspect hypersensitivity intolerance melphalan , dexamethasone , boron , mannitol , heparin , indwell catheter use Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrolment , New York Heart Association ( NYHA ) Class III IV heart failure ( Attachment 6 , NYHA Classification Cardiac Disease ) , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis History hypotension decrease blood pressure ( sit systolic blood pressure [ SBP ] &lt; = 100 mmHg and/or sit diastolic blood pressure [ DBP ] &lt; = 60 mmHg ) Serious medical psychiatric illness likely interfere participation clinical study Have receive experimental drug use experimental medical device within 4 week prior inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>high-dose melphalan</keyword>
	<keyword>bortezomib</keyword>
	<keyword>response</keyword>
	<keyword>toxicity</keyword>
	<keyword>relapse</keyword>
</DOC>